Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19244047 | 0.98 | KMT2A (0.68) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL1881377 | 0.97 | KMT2A (0.60) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL1936119 | 0.93 | KMT2A (0.55) | KMT2AAXLHPGDSADORA3ADORA1 | |
| SCHEMBL31074697 | 0.84 | KMT2A (0.48) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL1934159 | 0.83 | KMT2A (0.69) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL1937546 | 0.81 | KMT2A (0.71) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL1783010 | 0.80 | KMT2A (0.65) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL13812811 | 0.80 | KMT2A (0.65) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL22866360 | 0.80 | KMT2A (0.97) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL1976634 | 0.80 | KMT2A (0.65) | KMT2AAXLHPGDSPDE10AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994171-A | Preparation method of rebamacinib intermediate 2-chloro-7-cyclopentyl-7H-pyrrolo [2,3-d ] pyrimidine-6-methanol | 浙江工业大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-114751909-B | Preparation method of rebaudinib intermediate | 杭州福斯特药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114751909-A | Preparation method of Ribociclib intermediate | 杭州福斯特药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-108586356-B | Ribociclib new intermediate and synthetic method for preparing Ribociclib by using same | 杭州科巢生物科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3357922-B1 | 2-((5-(1-(3-(METHYLSULFONYL)PROPYL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS CDK4 INHIBITORS FOR TREATING TUMORS | GUANGZHOU BEBETTER MEDICINE TECH CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-10183941-B2 | Pyrimidine or pyridopyridone compound and application thereof | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| EP-3357922-A1 | PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| CN-105622638-A | Pyrimido or pyridopyridone compound and its preparation method and use | GUANGZHOU KANGSHENG BEITE PHARMACEUTICAL CO LTD | 2016-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183941-B2 | Pyrimidine or pyridopyridone compound and application thereof | CDK6, CDK4, CDK2 | KMT2A 1221/4885AXL 531/4885HPGDS 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.